construction release_alert

Profile editing is temporarily unavailable from June 11-24, 2026
while manual profile data entry transitions to Elements. Learn More.

cancel

Thomas Lawrence Holland

Professor of Medicine

Medicine, Infectious Diseases

Duke Box 102359, Durham, NC 27710

Room 163 Hanes House, Trent Drive, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education

Academic Experience

Expertise

Research
1. Selected Grants
2. External Relationships

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities
1. Outreach & Engaged Scholarship

Embed Profile Data

Embed Profile Data

Current Appointments & Affiliations

Professor of Medicine · 2024 - Present Medicine, Infectious Diseases, Medicine

Membership in the Duke Clinical Research Institute · 2015 - Present Duke Clinical Research Institute, Institutes and Centers

In the News

Published October 4, 2023

Drug Found Effective in Fighting Deadly Infections

Published July 11, 2022

Monoclonal Antibody Treatment Reduced Deaths in Hospitalized COVID Patients

Published September 26, 2018

New Way of Determining Treatment for Staph Infections Cuts Antibiotic Use

Recent Publications

Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial

Journal Article CMI Communications · July 2026 Full text Cite

Passive immunotherapy for COVID-19: the long and the short of it.

Journal Article Clin Microbiol Infect · April 2026 Full text Link to item Cite

Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial.

Journal Article JAMA Netw Open · April 1, 2026 IMPORTANCE: Dalbavancin is an alternative to prolonged intravenous therapy for complicated Staphylococcus aureus bacteremia, yet its pharmacokinetics (PK) in patients with this condition are uncertain. OBJECTIVE: To characterize dalbavancin PK and evaluate ... Full text Open Access Link to item Cite

View All Publications

Recent Grants

A PHASE 3 EFFICACY AND SAFETY STUDY OF FOSMANOGEPIX FOR THE TREATMENT OF ADULT PARTICIPANTS WITH CANDIDEMIA AND/OR INVASIVE CANDIDIASIS

ResearchInvestigator · Awarded by Basilea Pharmaceutica International Ltd, Allschwil · 2026 - 2028

Invasive Candidiasis

Clinical TrialPrincipal Investigator · Awarded by Basilea Pharmaceutica · 2024 - 2028

Antibacterial Resistance Leadership Group (ARLG)

ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2013 - 2026

View All Grants

Education

Wake Forest University · 2005 M.D.